Key Takeaways AbbVie has submitted an FDA application for tavapadon to treat Parkinson's disease.TEMPO studies showed tavapadon improved symptoms across a broad Parkinson's disease population.If approved, tavapadon would be AbbVie's second recent Parkinson's therapy clearance.AbbVie (ABBV) announced that it has submitted a regulatory filing with the FDA, which seeks approval for its investigational drug tavapadon as a once-daily oral treatment for Parkinson’s disease (PD).The FDA filing is supported by resu ...

Accessibility StatementSkip Navigation NORTH CHICAGO, Ill., Sept. 29, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the start of construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, Illinois. This is a significant milestone in AbbVie's ongoing efforts to expand its U.S. manufacturing network, capabilities and capacity. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+Newsrooms &Influencers 9k+Digital MediaOutlets Continue Reading AbbVie ...

Accessibility StatementSkip Navigation The majority of adverse events were non-serious and mild or moderate in severity across TEMPO-1 through 3. The incidence of SAEs and deaths were low and comparable between placebo and tavapadon groups. The most common adverse reactions reported in 10% of patients were nausea, headache and dizziness for Parkinson's disease patients without levodopa, and nausea and dyskinesia for patients on adjunctive therapy with levodopa. NORTH CHICAGO, Ill., Sept. 26, 2025 /PRNewswir ...